Amgen has recently been told by the FDA to reword the labeling of its flagship anemia drugs – Aranesp and Procrit – to further restrict their use in treating cancer patients.
The move, which the F.D.A. announced on Wednesday, represents the first time the agency has invoked authority under a 2007 law that empowered it to order changes in a drug’s prescribing information. Previously, the F.D.A. could only negotiate with a drug’s manufacturer to change the label.
Sales of the drugs, Aranesp and Procrit, have already plummeted in the last year because of studies suggesting that their use to treat the …read more

Wow, it’s Monday again!? Yeah it is. Another manic Monday…
I hope you guys had a great weekend. I hope you are recharged, rested and was able to unwind.
Here are the top five I found today, at the cancer front:

Fat Women ‘At Greater Cancer Risk’
Alzheimer’s or cancer: Which disease would you rather die from?
Eating broccoli can help prevent bladder cancer
Boy’s cancer project takes off
Amgen To Use Lab21 Diagnostic Test For Cancer Gene

Well, that’s all for now folks! I hope you are up and about for the daily grind this week.